NAVIPPRO SIGNAL NEWSLETTER

Sign up for our monthly newsletter covering all topics related to NAVIPPRO SIGNAL.

Sign Up

Details  |  View Archive

home > offerings > risk management consulting > navippro

NAVIPPRO™

The National Addictions Vigilance Intervention and Prevention Program™ (NAVIPPRO) is the premier risk management program for prescription opioids, stimulants and other selected therapeutic agents.

With prescription drug abuse becoming increasingly prevalent in the United States, NAVIPPRO provides pharmaceutical companies with national, real-time, product-specific data for:

  • Postmarketing surveillance
  • Signal detection and verification
  • Intervention and prevention

 

 

NAVIPPRO includes two proprietary components that represent unique and valuable data streams for surveillance of prescription medication abuse: ASI-MV® Connect and Web-Informed Services (WIS™):  Internet Monitoring and Surveys on Prescription Drug Misuse. NAVIPPRO subscriptions enable subscribers to include these unique educational program in their REMS: PainEDU.org®, painACTION.com® and MyStudentBody®-Drugs .

FEATURES

  • Developed with the support of the National Institutes of Health and the pharmaceutical industry.
  • Helps meet FDA requirements for comprehensive risk management programs for schedule II and III prescription drugs.
  • Provides detailed reports on vigilance and surveillance available to subscribers.
  • Provides data source for ASI-MV Connect: Inflexxion's national network of substance abuse facilities.
  • Provides data sources for Web-Informed Services (WIS):  Internet Monitoring and Surveys on Prescription Drug Misuse.
  • Provides data streams including the FDA Adverse Event Reporting System (FDA AERS), Drug Abuse Warning Network (DAWN), American Association of Poison Control Centers' New Core System Database (NCSBeta), Drug Enforcement Agency news and Medline articles.